Our aim was to investigate the effects of interferons (IFNs)-λ (interleukin-29 [IL-29], IL-28A, and IL-28B) on hepatitis C virus (HCV) and hepatitis A virus (HAV) internal ribosomal entry site (IRES)-mediated translation. The effects of these IFNs on HCV/HAV translation from HAV/HCV IRES were investigated using bicistronic reporter constructs. We transfected HCV/HAV IRES constructs into these IFN-expressing cell lines. IL-29 showed stronger inhibition of their IRES-mediated translation. Combining IL-29 with IFN-α or amantadine resulted in stronger inhibition of HAV IRES activity. Our findings demonstrated a novel antiviral effect of IFNs-λ against HAV and HCV through the suppression of IRES-mediated translation.
Get full access to this article
View all access options for this article.
References
1.
BaconBR, KhalidO. New therapies for hepatitis C virus infection. Mo Med, 2011; 108:255–259.
2.
BalvayL, Soto RifoR, RicciEP, DecimoD, OhlmannT. Structural and functional diversity of viral IRESes. Biochim Biophys Acta, 2009; 1789:542–557.
3.
BasuA, MeyerK, LaiKKet al.Microarray analyses and molecular profiling of Stat3 signaling pathway induced by hepatitis C virus core protein in human hepatocytes. Virology, 2006; 349:347–358.
4.
CordesS, KusovY, HeiseT, Gauss-MullerV. La autoantigen suppresses IRES-dependent translation of the hepatitis A virus. Biochem Biophys Res Commun, 2008; 368:1014–1019.
5.
DiegelmannJ, BeigelF, ZitzmannKet al.Comparative analysis of the lambda-interferons IL-28A and IL-29 regulating their transcriptome and their antiviral properties against hepatitis C virus. PLoS One, 2010; 5:e1522.
6.
DoyleSE, SchreckhiseH, Khuu-DuongKet al.Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology, 2006; 44:896–906.
7.
DunnC, PeppaD, KhannaPet al.Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology, 2009; 137:1289–1300.
8.
FujiwaraK, KojimaH, YonemitsuYet al.Phylogenetic analysis of hepatitis A virus in sera from patients with hepatitis A of various severities. Liver Int, 2009; 29:838–845.
9.
Gauss-MullerV, KusovYY. Replication of a hepatitis A virus replicon detected by genetic recombination in vivo. J Gen Virol, 2002; 83:183–192.
10.
GeD, FellayJ, ThompsonAJet al.Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature, 2009; 461:399–401.
11.
GlassMJ, JiaXY, SummersDF. Identification of the hepatitis A virus internal ribosome entry site: in vivo and in vitro analysis of bicistronic RNAs containing the HAV 5’ noncoding region. Virology, 1993; 193:842–852.
12.
GlassMJ, SummersDF. Identification of a trans-acting activity from liver that stimulates hepatitis A virus translation in vivo. Virology, 1993; 193:1047–1050.
13.
ItoT, TaharaSM, LaiMM. The 3’-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J Virol, 1998; 72:8789–8796.
14.
KandaT, BasuA, SteeleRet al.Generation of infectious hepatitis C virus in immortalized human hepatocytes. J Virol, 2006; 80:4633–4639.
15.
KandaT, ImazekiF, NakamotoS, OkitsuK, FujiwaraK, YokosukaO. Internal ribosomal entry-site activities of clinical isolate-derived hepatitis A virus and inhibitory effects of amantadine. Hepatol Res, 2010; 40:415–423.
16.
KandaT, ImazekiF, YokosukaO. New antiviral therapies for chronic hepatitis C. Hepatol Int, 2010; 4:548–561.
17.
KandaT, JeongSH, ImazekiF, FujiwaraK, YokosukaO. Analysis of 5' nontranslated region of hepatitis A viral RNA genotype I from South Korea: comparison with disease severities. PLoS One, 2010; 5:e15139.
18.
KandaT, SteeleR, RayR, RayRB. Small interfering RNA targeted to hepatitis C virus 5' nontranslated region exerts potent antiviral effect. J Virol, 2007; 81:669–676.
19.
KandaT, YokosukaO, ImazekiF, FujiwaraK, NagaoK, SaishoH. Amantadine inhibits hepatitis A virus internal ribosomal entry site-mediated translation in human hepatoma cells. Biochem Biophys Res Commun, 2005; 331:621–629.
20.
KandaT, ZhangB, KusovY, YokosukaO, Gauss-MullerV. Suppression of hepatitis A virus genome translation and replication by siRNAs targeting the internal ribosomal entry site. Biochem Biophys Res Commun, 2005; 330:1217–1223.
21.
KatoJ, KatoN, MoriyamaMet al.Interferons specifically suppress the translation from the internal ribosome entry site of hepatitis C virus through a double-stranded RNA-activated protein kinase-independent pathway. J Infect Dis, 2002; 186:155–163.
22.
KiyoharaT, TotsukaA, YoneyamaT, IshiiK, ItoT, WakitaT. Characterization of anti-idotypic antibodies mimicking antibody- and receptor-binding sites on hepatitis A virus. Arch Virol, 2009; 154:1263–1269.
23.
KomarAA, HatzoglouM. Internal ribosome entry sites in cellular mRNAs: mystery of their existence. J Biol Chem, 2005; 280:23425–23428.
24.
KorfM, JarczakD, BegerC, MannsMP, KrugerM. Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. J Hepatol, 2005; 43:225–234.
25.
KotenkoSV, GallagherG, BaurinVVet al.IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol, 2003; 4:69–77.
26.
LicursiM, KomatsuY, PongnopparatT, HirasawaK. Promotion of viral IRES-mediated translation under amino acid starvation. J Gen Virol, 2012; 93:951–962.
27.
LiJ, LinS, ChenQet al.Inhibition of hepatitis B virus replication by MyD88 involves accelerated degradation of pregenomic RNA and nuclear retention of pre-S/S RNAs. J Virol, 2010; 84:6387–6399.
28.
LiQ, KawamuraK, MaGet al.Interferon-lambda induces G1 phase arrest or apoptosis in oesophageal carcinoma cells and produces anti-tumour effects in combination with anti-cancer agents. Eur J Cancer, 2010; 46:180–190.
29.
MaD, JiangD, QingMet al.Antiviral effect of interferon lambda against West Nile virus. Antiviral Res, 2009; 83:53–60.
30.
MackiewiczV, CammasA, DesboisDet al.Nucleotide variability and translation efficiency of the 5' untranslated region of hepatitis A virus: update from clinical isolates associated with mild and severe hepatitis. J Virol, 2010; 84:10139–10147.
31.
MartinA, LemonSM. Hepatitis A virus: from discovery to vaccines. Hepatology, 2006; 43:S164–S172.
32.
MiyamuraT, IshiiK, KandaTet al.Possible widespread presence of hepatitis A virus subgenotype IIIA in Japan: Recent trend of hepatitis A causing acute liver failure. Hepatol Res, 2011; 42:248–253.
33.
MiyamuraT, KandaT, NakamotoSet al.Hepatic STAT1-nuclear translocation and interleukin 28B polymorphisms predict treatment outcomes in hepatitis C virus genotype 1-infected patients. PLoS One, 2011; 6:e28617.
34.
MordsteinM, NeugebauerE, DittVet al.Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. J Virol, 2010; 84:5670–5677.
35.
MuirAJ, ShiffmanML, ZamanAet al.Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection. Hepatology, 2010; 52:822–832.
36.
RobekMD, BoydBS, ChisariFV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol, 2005; 79:3851–3854.
37.
RobertsonBH, JansenRW, KhannaBet al.Genetic relatedness of hepatitis A strains recovered from different geographical regions. J Gen Virol, 1992; 73:1365–1377.
38.
SchultzDE, HondaM, WhetterLE, McKnightKL, LemonSM. Mutations within the 5’ nontranslated RNA of cell culture-adapted hepatitis A virus which enhance cap-independent translation in cultured African green monkey kidney cells. J Virol, 1996; 70:1041–1049.
39.
SheppardP, KindsvogelW, XuWet al.IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol, 2003; 4:63–68.
40.
ShimazakiT, HondaM, KanekoS, KobayashiK. Inhibition of internal ribosomal entry site-directed translation of HCV by recombinant IFN-alpha correlates with a reduced La protein. Hepatology, 2002; 35:199–208.
41.
SvetlikovaD, KabatP, OhradanovaA, PastorekJ, BetakovaT. Influenza A virus replication is inhibited in IFN-lambda2 and IFN-lambda3 transfected or stimulated cells. Antiviral Res, 2010; 88:329–333.
42.
TanakaY, NishidaN, SugiyamaMet al.Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet, 2009; 41:1105–1109.
43.
WakitaT, PietschmannT, KatoTet al.Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat Med, 2005; 11:791–796.
44.
WuS, KandaT, ImazekiFet al.Hepatitis B virus e antigen downregulates cytokine production in human hepatoma cell lines. Viral Immunol, 2010; 23:467–476.
45.
YangL, KiyoharaT, KandaTet al.Inhibitory effects on HAV IRES-mediated translation and replication by a combination of amantadine and interferon-alpha. Virol J, 2010; 7:212.
46.
YiM, SchultzDE, LemonSM. Functional significance of the interaction of hepatitis A virus RNA with glyceraldehyde 3-phosphate dehydrogenase (GAPDH): opposing effects of GAPDH and polypyrimidine tract binding protein on internal ribosome entry site function. J Virol, 2000; 74:6459–6468.
47.
YuML, HuangCF, HuangJFet al.Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients. Hepatology, 2011; 53:7–13.
48.
ZhouZ, HammingOJ, AnkN, PaludanSR, NielsenAL, HartmannR. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. J Virol, 2007; 81:7749–7758.
49.
ZhuH, ButeraM, NelsonDR, LiuC. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J, 2005; 2:80.
